Who
James R. Neal
Director
Company insider
Files Form 4 as: Director, Processa Pharmaceuticals; Director, Akari Therapeutics; Director, Peak Bio; Director, Palisade Bio; CEO, Xoma.
In numbers
- Trades disclosed
- 166
- Buys
- 4
- Sells
- 29
- Bought
- $88K
- Sold
- $7.0M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 18 Mar 2014
- Last trade
- 26 Jul 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jul 2026filed 28 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,221 at $0.00 | filing |
| 26 Jul 2026filed 28 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,221 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —203 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —203 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —203 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —203 | filing |
| 31 Mar 2026filed 2 Apr 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,000789 at $2.54 | filing |
| 31 Mar 2026filed 2 Apr 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,004789 at $2.54 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,473 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $9992,473 at $0.4041 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,093 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,473 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $9892,473 at $0.40 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,093 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1,2373,093 at $0.40 | filing |
| 16 Dec 2025filed 16 Mar 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1,2503,093 at $0.4041 | filing |
| 1 Oct 2025filed 3 Oct 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 24 Jul 2025filed 28 Jul 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,299 at $0.00 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.